Nemera designs, develops and manufactures parenteral (passive safety devices autoinjectors, pens, and implanters), nasal, buccal, auricular, ophthalmic, pulmonary, dermal and transdermal drug delivery devices for the pharmaceutical, biotechnology and generics industries.
63-65, avenue Tony Garnier
Phone / ContactT: +33 4 74 94 06 54
F: +33 4 74 94 90 60
E: [email protected]
Nemera is one of the world’s leading designers, developers and manufacturers of drug delivery devices for the pharmaceutical, biotechnology and generics industries. It uses different types of business model including full solution development, pure contract manufacturing, and customised solutions.
Nemera’s areas of expertise include numerous modes of delivery: parenteral, nasal, buccal, auricular, ophthalmic, pulmonary, dermal and transdermal.
The company has more than 100 engineers working in development, over 30000 m2 of clean-room manufacturing, sales in 47 countries, over one billion devices produced yearly, and more than 1950 employees. Nemera has four plants in Europe and the US at: Neuenburg, Germany; La Verpillière, France (see below); Le Tréport, France; and Buffalo Grove, IL, US.
Today Nemera is owned 50% by Montagu Private Equity (London, UK) and 50% by Astorg (Paris, France). Nemera was created in 2014 when Montagu acquired the Healthcare and Retail Prescription divisions of Rexam (now Ball Corporation). The Healthcare division was renamed Nemera shortly after the acquisition.
In August 2019, Nemera acquired US healthcare focused design and innovation consultancy Insight Product Development and integrated it into its new Insight Innovation Center.